Real moms, real GLP-1 talk
Zepbound vs Wegovy: Which Is Right for You?
Zepbound and Wegovy compared through trial results, side effects, cost, pregnancy planning and contraception, with the limits of the evidence.
On this page
- The short version, mom to mom
- The head-to-head data (finally a real one)
- Side effects: same family, mostly during the dose climbs
- Staying there: the maintenance question a mom actually asks
- Cost and access (the part that decided it for a lot of us)
- The mom-specific stuff a brand comparison skips
- How I'd actually choose
The short version, mom to mom
I would begin a Zepbound–Wegovy comparison with the direct evidence, then ask whether the practical differences fit my circumstances. These are different molecules, and in adults the head-to-head trial found greater average weight loss with tirzepatide over 72 weeks1; teenagers raise separate pediatric questions. That result answers an important question without answering every question about treatment.
Side effects, cost, pregnancy plans and contraception still belong in the decision. I would want the prescriber to connect the trial result to my medical history rather than treat the larger average as a universal recommendation.
Zepbound contains tirzepatide and Wegovy contains semaglutide. The same molecules also appear in Mounjaro and Ozempic, which have diabetes indications. I would check the actual brand, formulation and indication rather than assume a familiar name describes the same prescription or insurance pathway.
The head-to-head data (finally a real one)
For a long time these comparisons leaned on separate trials, which is a bit like arguing whose kid is taller from two different school photos. Now there's a direct one. SURMOUNT-5 randomized 751 adults with obesity to Zepbound or Wegovy for 72 weeks at their maximum tolerated doses. Mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide, and tirzepatide came out superior for both weight and waist-circumference reduction1.
That tracks with each drug's own pivotal trial — semaglutide produced about 15% average weight loss in STEP 12, and tirzepatide about 20% at the top dose in SURMOUNT-13 — so this isn't one weird study. The direction is consistent across the evidence.
The honest caveat I keep reminding myself of: "more on average" is a fact about groups, not about me. Plenty of women lose a lot on semaglutide, tolerate it better, or pay less for it, and the newer Wegovy 7.2 mg dose has its own trial that should not be blended into this one. The trial tells you where the averages point, not where any single mom lands.
Side effects: same family, mostly during the dose climbs
Both are built on GLP-1 signaling (Zepbound adds a second target, GIP, and the still-unapproved retatrutide adds a third, glucagon), so the side-effect profile rhymes. The gastrointestinal stuff — nausea, diarrhea, constipation, vomiting — is the most common with both, most of it is mild to moderate, and it clusters during the dose-escalation phase rather than at a stable maintenance dose1. Neither one is reliably the "gentle" option; tolerance is personal. A good program titrates slowly and switches you if a molecule just doesn't sit right.
Staying there: the maintenance question a mom actually asks
Weight loss that snaps back the second you stop isn't the goal, and this is where the mom lens earns its keep. Both drugs are studied as ongoing treatments. When semaglutide was stopped and switched to placebo, much of the lost weight came back4. Continuing tirzepatide, on the other hand, held the reduction where stopping did not5. If you might pause treatment for a pregnancy someday, "what happens when I stop, and how do I restart?" is a far more useful question than "which number is bigger?"
Cost and access (the part that decided it for a lot of us)
The relevant cost is the actual prescription and dose, including a visit or membership where required. Current manufacturer offers are in my self-pay Zepbound and Wegovy price list, and a telehealth route changes the shape of the bill: Shed, for example, lists real brand-name Wegovy and Zepbound alongside its compounded options, though the brand prescriptions there carry a separate $125-a-month membership, so I would compare like with like. If insurance might pay, Found Health offers brand pens and works with a named carrier list and a coverage-checker tool, though its insurance route requires video visits and visit copays. I would confirm my own plan’s coverage and renewal total before choosing based on a headline.
The mom-specific stuff a brand comparison skips
Two facts matter here that a straight efficacy chart leaves out completely:
- Birth control. The Zepbound label carries an explicit warning that oral hormonal contraceptives may become less effective, and it advises switching to a non-oral method or adding a barrier method around starting the drug and around each dose increase6. I went and read the Wegovy labeling myself afterwards, and it does not carry that specific warning, which I went through line by line in semaglutide and birth control pills. If I used oral contraception, I would ask for a specific plan before starting or increasing tirzepatide rather than treat that warning as a footnote.
- Breastfeeding and pregnancy timing. This is the one place the two genuinely part company. Wegovy's label asks you to stop at least two months before a planned pregnancy; Zepbound's sets no pre-pregnancy window and says to stop once a pregnancy is recognized. That "week per dose" figure everyone quotes is the half-life, not the instruction. Breastfeeding needs a separate discussion. The current Zepbound label reports a small single-dose milk study with low measured transfer, while infant-outcome evidence remains limited. Injectable semaglutide and oral Wegovy also have different lactation information. Low transfer alone does not establish infant safety.
How I'd actually choose
The averages favor Zepbound, but averages aren't people. Tolerance, cost, what your insurance covers, whether you take the pill, and your pregnancy plans all feed a real decision. If a change is being considered, the questions about switching from Wegovy to Zepbound belong with the prescriber. Bring your history and your plans to a clinician and decide together — don't pick from a brand name.
Frequently asked questions
Is Zepbound better than Wegovy?
In the SURMOUNT-5 head-to-head trial, Zepbound (tirzepatide) produced more weight loss than Wegovy (semaglutide) over 72 weeks — about 20% versus 14% — and was declared superior. But that's an average across groups, not a promise for you. Tolerance, cost, insurance coverage, and contraception all matter, and a good program can switch you if the first molecule isn't right.
Does the choice matter if I'm on the pill?
Yes. Zepbound advises oral hormonal contraceptive users to switch to a non-oral method or add a barrier method for four weeks after starting and four weeks after each dose increase. Wegovy does not carry that specific instruction. Tell the prescriber which contraception you use and discuss pregnancy plans before treatment.
Can I use either while breastfeeding or pregnant?
For weight management, pregnancy and pregnancy planning require a prescriber’s advice: Wegovy specifies stopping at least two months before a planned pregnancy; Zepbound says to discontinue when pregnancy is recognized without naming a pre-pregnancy interval. Breastfeeding is a separate question. Zepbound’s current label includes a small single-dose milk study, which does not establish infant safety. Oral and injectable Wegovy also have different lactation information. Get the actual treatment and feeding plan from your clinician.
References
- Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. https://pubmed.ncbi.nlm.nih.gov/33755728/
- Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. https://pubmed.ncbi.nlm.nih.gov/38078870/
- U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) injection — Prescribing Information (Drug Interactions: Oral Contraceptives). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
One mom to another, not a doctor: everything here is for learning and figuring out your options, not medical advice, a diagnosis, or a plan for your body. Pregnancy planning and breastfeeding need advice for the exact medicine and formulation. Before you start, stop, or change anything, talk it through with a clinician who actually knows your history.
Continue reading
Zepbound and PCOS: What I Found When I Went Looking for the Evidence
How Zepbound’s approved uses differ from PCOS-specific evidence, what the small tirzepatide-plus-metformin trial found, and questions about contraception.
ReadGLP-1s and Alcohol: What Craving Research Shows
What small randomized trials show about GLP-1s and alcohol craving, what they do not establish, and questions about symptoms and other medicines.
ReadI Went Looking for the Wegovy-to-Zepbound Conversion Chart. There Isn't One.
Everyone searches for a dosage conversion chart. I read all three labels end to end — no conversion exists. Here is what they actually say about switching.
ReadOzempic Face: What Weight-Loss Research Can Explain
What research can explain about facial changes after GLP-1 weight loss, which claims remain uncertain, and questions to ask about proposed solutions.
ReadThe GLP-1 Timeline: What Actually Happens Month by Month
How to read a GLP-1 treatment timeline without turning trial averages into personal deadlines, with questions about symptoms, dose reviews and maintenance.
ReadMicrodosing GLP-1s: The Honest Take on the Hype
What low-dose GLP-1 marketing means, what dose-response trials can support, and the questions to ask about monitoring, cost and compounded products.
Read